Considerations for povidone-iodine antisepsis in pediatric nasal and pharyngeal surgery during the COVID-19 pandemic.
Am J Otolaryngol
; 41(6): 102737, 2020.
Article
in English
| MEDLINE | ID: covidwho-799098
ABSTRACT
PURPOSE:
Surgeons resuming elective procedures during the COVID-19 pandemic should consider strategies to mitigate risk of exposure. For otolaryngologists performing surgery on children, unique vulnerability to SARS-CoV-2 results from a regular interface with the upper respiratory tract mucosa. A growing interest in perioperative application of povidoneiodine (PVP-I) to the nasopharynx and oropharynx has emerged. The purpose of this review is to provide an evidence-based assessment of PVP-I in pediatric oral, nasal and pharyngeal surgery.METHODS:
A contemporary literature review with algorithmic approach to the potential use of PVP-I in pediatric mucosal surgery.RESULTS:
Several formulations of PVP-I have shown rapid in vitro virucidal activity against SARS-CoV-2. Antisepsis using 1.0% PVP-I mouthwash and 0.45% PVP-I throat spray can occur after 30 seconds of contact time. To date, in vivo effectiveness of PVP-I against SARS-CoV-2 has yet to be established and possible risks of its direct use on upper aerodigestive mucosa of children must be weighed.CONCLUSION:
Further research is required prior to strongly recommending PVP-I use in preparation for nasal, oral or pharyngeal surgery in children.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Povidone-Iodine
/
Otorhinolaryngologic Surgical Procedures
/
Infectious Disease Transmission, Patient-to-Professional
/
Coronavirus Infections
/
Pandemics
/
Anti-Infective Agents, Local
Type of study:
Observational study
/
Prognostic study
/
Reviews
Limits:
Child
/
Humans
Language:
English
Journal:
Am J Otolaryngol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS